193 related articles for article (PubMed ID: 38454344)
21. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Chen JC; Lee IN; Huang C; Wu YP; Chung CY; Lee MH; Lin MH; Yang JT
BMC Cancer; 2019 Aug; 19(1):756. PubMed ID: 31370819
[TBL] [Abstract][Full Text] [Related]
22. NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
Tsuji S; Nakamura S; Shoda K; Yamada T; Shimazawa M; Nakayama N; Iwama T; Hara H
J Neurooncol; 2022 Nov; 160(2):375-388. PubMed ID: 36308592
[TBL] [Abstract][Full Text] [Related]
23. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
24. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
27. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
29. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Shang C; Tang W; Pan C; Hu X; Hong Y
Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
Jin L; Kiang KM; Cheng SY; Leung GK
Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
[TBL] [Abstract][Full Text] [Related]
31. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
[TBL] [Abstract][Full Text] [Related]
32. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
34. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
[TBL] [Abstract][Full Text] [Related]
35. A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas.
Ho KH; Chen PH; Chou CM; Shih CM; Lee YT; Cheng CH; Chen KC
Neurotherapeutics; 2020 Jul; 17(3):1212-1227. PubMed ID: 31916238
[TBL] [Abstract][Full Text] [Related]
36. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
37. PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma.
Yang E; Wang L; Jin W; Liu X; Wang Q; Wu Y; Tan Y; Wang Y; Cui X; Zhao J; Tong F; Hong B; Xiao M; Liu X; Fang C; Kang C
Theranostics; 2022; 12(9):4330-4347. PubMed ID: 35673568
[No Abstract] [Full Text] [Related]
38. ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression.
Yang JT; Lee IN; Huang C; Huang HC; Wu YP; Chong ZY; Chen JC
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175410
[TBL] [Abstract][Full Text] [Related]
39. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
He Y; Kaina B
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
[TBL] [Abstract][Full Text] [Related]
40. Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.
Wu L; Yang L; Xiong Y; Guo H; Shen X; Cheng Z; Zhang Y; Gao Z; Zhu X
Tumour Biol; 2014 Dec; 35(12):12327-37. PubMed ID: 25245332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]